Filing Flows › Insight Molecular Diagnostics (IMDX) › Q3 2025
Insight Molecular Diagnostics (IMDX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Insight Molecular Diagnostics (IMDX) reported revenue of $260K for the third quarter 2025 (Q3 2025), +126% from a year earlier and -50% from the quarter before.
Insight Molecular Diagnostics, Q3 2025: revenue $260K (+126% year over year), net loss $10.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $260K | -50% | +126% |
| Operating profit | −$11.0M | — | — |
| Net earnings | −$10.9M | — | — |
| Operating cash flow | −$4.6M | — | — |
What changed
Revenue was $260K in Q3 2025, up 126% year over year and down 50% from the previous quarter.
Gross margin was 53.5%, up 10.0 points from a year earlier. Operating costs exceeded revenue by $11.0M, an operating margin of -4249.2%. Operating expenses fell 18% while revenue rose 126%. The fastest-growing cost line was Research & development (+38%). The quarter ended with a net loss of $10.9M, wider than the previous quarter's $9.7M loss.
Operating cash flow was −$4.6M. Non-cash charges added back $584K of depreciation and amortization and $521K of share-based compensation. Working capital and other items added $5.1M. Capital expenditures of $1.1M exceeded it, leaving free cash flow of −$5.7M.
Questions
What was Insight Molecular Diagnostics' revenue in the third quarter 2025?
Insight Molecular Diagnostics (IMDX) reported revenue of $260K for the third quarter 2025 (Q3 2025), +126% from a year earlier and -50% from the quarter before.